- Previous Close
4.1200 - Open
4.1500 - Bid 4.1100 x --
- Ask 4.1500 x --
- Day's Range
4.0800 - 4.1500 - 52 Week Range
3.0700 - 6.4900 - Volume
43,400 - Avg. Volume
34,663 - Market Cap (intraday)
148.058M - Beta (5Y Monthly) 1.54
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0800 - Earnings Date Mar 20, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.12
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
www.eupraxiapharma.comRecent News: EPRX.TO
View MorePerformance Overview: EPRX.TO
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EPRX.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EPRX.TO
View MoreValuation Measures
Market Cap
147.70M
Enterprise Value
145.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
60.96
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-61.14%
Return on Equity (ttm)
-157.31%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-25.93M
Diluted EPS (ttm)
-1.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
33.1M
Total Debt/Equity (mrq)
0.23%
Levered Free Cash Flow (ttm)
-20.95M